Weiying Gu

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Ejection Fraction

Prognostic Factors

Multiple Myeloma

Chronic Myeloid Leukemia

Top Venues

Nature communications

Annals of hematology

Blood cancer journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Qian Wu, Xiaofei Yang, Jingren Zhang, Mengxing Xue, Xueqing Dou, Zheng Ge, Yifei Chen, Weiying Gu, Weimin Dong, Hongying Cao, Naike Jiang, Xuemei Sun, Zefa Liu, Jinning Shi, Hui Chen, Cixian Zhang, Fengling Min, Hongli Sun, Xiaoli Qian, Hongjian Yuan, Yuan Feng, De-Pei Wu, Suning Chen
Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia. Blood cancer journal 14 (1) (2024)
Qian Wu, Xiaofei Yang, Jingren Zhang, Mengxing Xue, Xueqing Dou, Zheng Ge, Yifei Chen, Weiying Gu, Weimin Dong, Hongying Cao, Naike Jiang, Xuemei Sun, Zefa Liu, Jinning Shi, Hui Chen, Cixian Zhang, Fengling Min, Hongli Sun, Xiaoli Qian, Hongjian Yuan, Yuan Feng, De-Pei Wu, Suning Chen
Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia. Blood cancer journal 14 (1) (2024)
Qian Wu, Xiaofei Yang, Jingren Zhang, Mengxing Xue, Xueqing Dou, Zheng Ge, Yifei Chen, Weiying Gu, Weimin Dong, Hongying Cao, Naike Jiang, Xuemei Sun, Zefa Liu, Jinning Shi, Hui Chen, Cixian Zhang, Fengling Min, Hongli Sun, Xiaoli Qian, Hongjian Yuan, Yuan Feng, De-Pei Wu, Suning Chen
Improved prevention and treatment strategies for differentiation syndrome contribute to reducing early mortality in patients with acute promyelocytic leukemia. Blood cancer journal 14 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Ning Guo, Jiaojiao Wang, Hongming Huang, Dan Liu, Hai Cheng, Xu Wang, Wei Chen, Zhiling Yan, Wei Sang, Kunming Qi, Depeng Li, Feng Zhu, Zhenyu Li, Jianlin Qiao, Qingyun Wu, Lingyu Zeng, Xiaoming Fei, Weiying Gu, Yuqing Miao, Kailin Xu, Jun-Nian Zheng, Jiang Cao
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial. Nature communications 15 (1) (2024)
Fei Wang, Luo Lu, HuiJuan Chen, Yanhua Yue, Yanting Sun, Feng Yan, Bai He, Rongrong Lin, Weiying Gu
Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab. Annals of hematology (2023)
Fei Wang, Luo Lu, HuiJuan Chen, Yanhua Yue, Yanting Sun, Feng Yan, Bai He, Rongrong Lin, Weiying Gu
Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab. Annals of hematology 102 (2) (2023)
Fei Wang, Luo Lu, HuiJuan Chen, Yanhua Yue, Yanting Sun, Feng Yan, Bai He, Rongrong Lin, Weiying Gu
Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab. Annals of hematology 102 (2) (2023)
Fei Wang, Luo Lu, HuiJuan Chen, Yanhua Yue, Yanting Sun, Feng Yan, Bai He, Rongrong Lin, Weiying Gu
Altered serum lipid levels are associated with prognosis of diffuse large B cell lymphoma and influenced by utility of rituximab. Annals of hematology 102 (2) (2023)
Kailin Xu, Jiang Cao, Weiying Gu, Ming Shi, Jianping Lan, Zhiling Yan, Lai Jin, Jieyun Xia, Sha Ma, Yang Liu, Hujun Li, Bin Pan, Wei Chen, Xiaoming Fei, Chunling Wang, Xiaobao Xie, Liang Yu, Gang Wang, Huizhong Li, Guangjun Jing, Hai Cheng, Feng Zhu, Haiying Sun, Wei Sang, Depeng Li, Zhenyu Li, Junnian Zheng
Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (20) (2022)
Yang Cao, Huizhuang Shan, Meng Liu, Jia Liu, Zilu Zhang, Xiaoguang Xu, Yue Liu, Hanzhang Xu, Hu Lei, Miao Yu, Xingming Zhang, Wanting Liu, Zhilei Bu, Zhixiao Fang, Yanjie Ji, Hua Yan, Weiying Gu, Ying-Li Wu
Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib. Cell death & disease 12 (4) (2021)